MIT Office of Innovation works with MIT founders and Alumni to aggregate Summer 2023 internship opportunities
The call is for startups in mobility, materials, logistics, energy, smart factory and construction.
P&G is seeking new communication methods, new ways of engaging consumers, and ways to create novel brand experiences.
Anglo American, a British mining company, is looking for startups in bio technology, rapid access, improved recovery, dry processing, mining legacy, sensor fusion, and EPC disruption.
Does your startup have a solution for urgent Covid-19 needs? Ideally they should be validated to work and demonstrate feasibility to scale. And could contacts to corporates help you scale up? MIT Startup Exchange is looking to help you connect.
Leading Japanese manufacturer of functional materials seeks startups for development of new applications for piezoelectric film.
Join Sandler trainer and consultant Joe Ippolito on May 18 from 11:00 AM to 12:30 PM ET for a free workshop on developing your sales tactics.
The Japan/Korean Startup Showcases is seeking startups to present and exhibit at three showcase events to be held in Osaka, Tokyo and Seoul.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.